ATM and melanoma: In this paper, we will depict the current evidence on the effect of PARP, ATM, CHK1, WEE1 and ATR inhibitors both in preclinical and clinical settings in melanoma (Figure 1), both as monotherapy and in combination with other targets belonging to the pathways crucial for melanoma proliferation and survival.